Drug Patent Law Reform

Venue: Sheraton Ottawa

Location: Ottawa, Ontario, Canada

Event Date/Time: Aug 31, 2004 End Date/Time: Sep 01, 2004
Registration Date: Jul 16, 2004
Early Registration Date: Jun 18, 2004
Report as Spam


Conference Chair:

Mr. David Tobin
Commissioner of Patents, Registrar of Trademarks and Chief Executive Officer
Canadian Intellectual Property Office

The limited period of market exclusivity provided by patent protection allows pharmaceutical companies to sustain research and development. This exclusive, executive-level forum will allow you to protect your high value intellectual property with sessions focused on:

-Intellectual property rights, innovation and public health

-The ethics of intellectual property rights and patents

-The evergreening policy debate: Latest concerns and developments

-How to acquire new intellectual property

Featuring 16 comprehensive case studies, discussions and practical presentations from global and domestic authorities in the intellectual property and patent pharmaceutical sectors!

Dr. Eric Noehrenberg
Director, International Trade and Market Issues,
International Federation of Pharmaceutical
Manufacturers Associations Dr Amir Attaran
International Development,
The Royal Institute of
International Affairs

Ms. Wendy J. Wagner
Attorney, Gowling Lafleur Henderson LLP

Dr. Richard Gold
Director, Centre for Intellectual Property Policy, McGill University

Mr. Benjamin L. England
Attorney, Hogan & Hartson LLP
and Former Regulatory Counsel,
Office of Regulatory Affairs,
U.S. Food and Drug Administration

Mr. Gerry Stobo
Attorney, Partner, Borden Ladner Gervais LLP

Mrs. Janet Lambert
President, BIOTECanada

Ms. Brigitte Kiecken
President and CEO, Biolyse Pharma Corporation

The Honorable Bruce A. Lehman
President & CEO, International Intellectual
Property Institute (IIPI)

Mr. John Theriault
Vice President, Corporate Security,

Dr. Alyna C. Smith
Ethics Officer, Human Genetics Programme,
World Health Organization

Ms. Susan D. Beaubien
Attorney, Partner & Fellow of the Intellectual Property, Institute of Canada, Borden Ladner Gervais LLP

Ms. Veronica McCaffrey
Senior Advisor, Intellectual Property Management, Partnership and Policy Development, Centre for Surveillance Coordination, Population and Public Health Branch, Health Canada

Mr. Anthony M. Keats
Attorney, Partner,
Keats McFarland & Wilson LLP

Mr. Adrian Zahl
Attorney, Ridout & Maybee LLP

Mr. Wayne Critchley
Executive Director, Patented Medicine Prices Review Board


150 Albert St.